Randomized phase II trial of S-1 versus S-1 plus irinotecan (IRIS) in patients with gemcitabine-refractory pancreatic cancer

被引：3
|
作者：
Mizuno, Nobumasa
Yamao, Kenji
Komatsu, Yoshito
Munakata, Masaki
Ishiguro, Atsushi
Yamaguchi, Taketo
Ohkawa, Shinichi
Kida, Mitsuhiro
Ioka, Tatsuya
Takeda, Koji
Kudo, Toshihiro
Kitano, Masayuki
Iguchi, Haruo
Tsuji, Akihito
Ito, Tetsuhide
Tanaka, Masao
Furuse, Junji
Hamada, Chikuma
Sakata, Yuh
机构：
[1] Aichi Canc Ctr Hosp, Dept Gastroenterol, Nagoya, Aichi 464, Japan
[2] Hokkaido Univ Hosp, Ctr Canc, Dept Canc Chemotherapy, Sapporo, Hokkaido, Japan
[3] Misawa City Hosp, Dept Med Oncol, Misawa, Japan
[4] Hirosaki Univ, Dept Med Oncol, Hirosaki, Aomori, Japan
[5] Chiba Canc Ctr, Div Gastroenterol, Chiba 2608717, Japan
[6] Kanagawa Canc Ctr Hosp, Hepatobiliary & Pancreat Oncol Div, Yokohama, Kanagawa, Japan
[7] Kitasato Univ, Sch Med, Dept Med, Sagamihara, Kanagawa 228, Japan
[8] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Hepatobiliary & Pancreat Oncol, Osaka, Japan
[9] Osaka City Gen Hosp, Dept Clin Oncol, Osaka, Japan
[10] Kinki Univ, Dept Med Oncol, Osaka, Japan
[11] Kinki Univ, Sch Med, Dept Gastroenterol & Hepatol, Osakasayama, Japan
[12] Natl Hosp Org, Shikoku Canc Ctr, Dept Gastroenterol, Matsuyama, Ehime, Japan
[13] Kochi Hlth Sci Ctr, Dept Med Oncol, Kochi, Japan
[14] Kyushu Univ, Dept Med & Bioregulatory Sci, Fukuoka 812, Japan
[15] Kyushu Univ, Dept Surg & Oncol, Fukuoka 812, Japan
[16] Kyorin Univ, Sch Med, Dept Internal Med, Mitaka, Tokyo 181, Japan
[17] Tokyo Univ Sci, Fac Engn, Tokyo 162, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期
关键词：
D O I：
10.1200/jco.2013.31.4_suppl.263
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
263
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
    T Ioka
    Y Komatsu
    N Mizuno
    A Tsuji
    S Ohkawa
    M Tanaka
    H Iguchi
    A Ishiguro
    M Kitano
    T Satoh
    T Yamaguchi
    K Takeda
    M Kida
    K Eguchi
    T Ito
    M Munakata
    T Itoi
    J Furuse
    C Hamada
    Y Sakata
    British Journal of Cancer, 2017, 116 : 464 - 471
  • [2] Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer
    Ioka, T.
    Komatsu, Y.
    Mizuno, N.
    Tsuji, A.
    Ohkawa, S.
    Tanaka, M.
    Iguchi, H.
    Ishiguro, A.
    Kitano, M.
    Satoh, T.
    Yamaguchi, T.
    Takeda, K.
    Kida, M.
    Eguchi, K.
    Ito, T.
    Munakata, M.
    Itoi, T.
    Furuse, J.
    Hamada, C.
    Sakata, Y.
    BRITISH JOURNAL OF CANCER, 2017, 116 (04) : 464 - 471
  • [3] Randomized phase II study of S-1 monotherapy versus gemcitabine plus S-1 in gemcitabine-refractory advanced pancreatic cancer.
    Ueno, Makoto
    Ohkawa, Shinichi
    Kobayashi, Noritoshi
    Sugimori, Kazuya
    Kawaguchi, Yoshiaki
    Kobayashi, Satoshi
    Taguri, Masataka
    Yamanaka, Takeharu
    Mine, Tetsuya
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [4] Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer
    S Ohkawa
    T Okusaka
    H Isayama
    A Fukutomi
    K Yamaguchi
    M Ikeda
    A Funakoshi
    M Nagase
    Y Hamamoto
    S Nakamori
    Y Tsuchiya
    H Baba
    H Ishii
    Y Omuro
    M Sho
    S Matsumoto
    N Yamada
    H Yanagimoto
    M Unno
    Y Ichikawa
    S Takahashi
    G Watanabe
    G Wakabayashi
    N Egawa
    M Tsuda
    R Hosotani
    C Hamada
    I Hyodo
    British Journal of Cancer, 2015, 112 : 1428 - 1434
  • [5] Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer
    Ohkawa, S.
    Okusaka, T.
    Isayama, H.
    Fukutomi, A.
    Yamaguchi, K.
    Ikeda, M.
    Funakoshi, A.
    Nagase, M.
    Hamamoto, Y.
    Nakamori, S.
    Tsuchiya, Y.
    Baba, H.
    Ishii, H.
    Omuro, Y.
    Sho, M.
    Matsumoto, S.
    Yamada, N.
    Yanagimoto, H.
    Unno, M.
    Ichikawa, Y.
    Takahashi, S.
    Watanabe, G.
    Wakabayashi, G.
    Egawa, N.
    Tsuda, M.
    Hosotani, R.
    Hamada, C.
    Hyodo, I.
    BRITISH JOURNAL OF CANCER, 2015, 112 (09) : 1428 - 1434
  • [6] RANDOMIZED PHASE II TRIAL OF S-1 VERSUS S-1 PLUS OXALIPLATIN (SOX) IN PATIENTS WITH GEMCITABINE REFRACTORY PANCREATIC CANCER
    Okusaka, T.
    Ohkawa, S.
    Isayama, H.
    Fukutomi, A.
    Yamaguchi, K.
    Ikeda, M.
    Funakoshi, A.
    Nagase, M.
    Nakamori, S.
    Hamamoto, Y.
    ANNALS OF ONCOLOGY, 2012, 23 : 241 - 242
  • [7] A randomized phase II study of S-1 plus oral leucovorin versus S-1 monotherapy in patients with gemcitabine-refractory advanced pancreatic cancer
    Ueno, M.
    Okusaka, T.
    Omuro, Y.
    Isayama, H.
    Fukutomi, A.
    Ikeda, M.
    Mizuno, N.
    Fukuzawa, K.
    Furukawa, M.
    Iguchi, H.
    Sugimori, K.
    Furuse, J.
    Shimada, K.
    Ioka, T.
    Nakamori, S.
    Baba, H.
    Komatsu, Y.
    Takeuchi, M.
    Hyodo, I.
    Boku, N.
    ANNALS OF ONCOLOGY, 2016, 27 (03) : 502 - 508
  • [8] Randomized phase II study comparing S-1 plus Leucovorin (SL) versus S-1 alone in patients with gemcitabine-refractory advanced pancreatic cancer (APC)
    Okusaka, T.
    Ueno, M.
    Omuro, Y.
    Isayama, H.
    Fukutomi, A.
    Ikeda, M.
    Mizuno, N.
    Fukuzawa, K.
    Hyodo, I.
    Boku, N.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S611 - S611
  • [9] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Morizane, Chigusa
    Okusaka, Takuji
    Furuse, Junji
    Ishii, Hiroshi
    Ueno, Hideki
    Ikeda, Masafumi
    Nakachi, Kohei
    Najima, Mina
    Ogura, Takashi
    Suzuki, Eiichiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (02) : 313 - 319
  • [10] A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer
    Chigusa Morizane
    Takuji Okusaka
    Junji Furuse
    Hiroshi Ishii
    Hideki Ueno
    Masafumi Ikeda
    Kohei Nakachi
    Mina Najima
    Takashi Ogura
    Eiichiro Suzuki
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 313 - 319
12345